WARRINGTON, Pa., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that management will present an overview and update on the Company's business at the 2012 Piper Jaffray Health Care Conference on Tuesday, November 27, 2012 at 12:50 pm ET at the New York Palace Hotel in New York, New York.
ABOUT DISCOVERY LABS
Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to advance a new standard in respiratory critical care. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized, and aerosolized dosage forms. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.
CONTACT: Investor Relations Michael Rice, LifeSci Advisors: 646.597.6979 or email@example.com John G. Cooper, President and Chief Financial Officer: 215.488.9490
Source:Discovery Laboratories, Inc.